NYKDO Stock Overview
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nykode Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr18.69 |
| 52 Week High | kr18.69 |
| 52 Week Low | kr18.69 |
| Beta | 1.44 |
| 1 Month Change | 0% |
| 3 Month Change | 1.49% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| NYKDO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 2.5% |
| 1Y | n/a | -22.0% | 5.8% |
Return vs Industry: Insufficient data to determine how NYKDO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how NYKDO performed against the UK Market.
Price Volatility
| NYKDO volatility | |
|---|---|
| NYKDO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: NYKDO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NYKDO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 168 | Michael Engsig | nykode.com |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10
Nykode Therapeutics AS Fundamentals Summary
| NYKDO fundamental statistics | |
|---|---|
| Market cap | kr5.75b |
| Earnings (TTM) | -kr449.25m |
| Revenue (TTM) | kr155.21m |
37.0x
P/S Ratio-12.8x
P/E RatioIs NYKDO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYKDO income statement (TTM) | |
|---|---|
| Revenue | US$14.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$14.52m |
| Other Expenses | US$56.54m |
| Earnings | -US$42.02m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 28, 2024
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -289.45% |
| Debt/Equity Ratio | 0% |
How did NYKDO perform over the long term?
See historical performance and comparison